A Study to Evaluate the Bioavailability of Two Specifications of Oral Deuremidevir Hydrobromide for Suspension

Phase 1 Completed 18 enrolled Vigonvita Life Sciences

RandomizedCrossoverOpen-labelTreatment

Summary

The goal of this clinical study is to evaluate the bioavailability of two specifications of oral Deuteriumremidvir Hydrobromide for suspension in Chinese healthy adult participants. A total of 18 participants are planned to be enrolled and randomized into T-R or R-T sequence, 9 in each sequence with a single fasting administration in each period.

Timeline

Start: 2025-08-11
Primary completion: 2025-08-20
Completion: 2025-09-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	deuteriumremidvir	Unknown	100 mg	Oral
Subject	deuteriumremidvir	Unknown	200 mg	Oral

Indications

No indication recorded.